Ua hauʻoli ʻo Hoffmann-La Roche Limited (Roche Canada) i ka hoʻolaha ʻana ma Ianuali 14, 2022, ua ʻae ʻo Health Canada iā TECENTRIQ.^® (atezolizumab) ma ke ʻano he monotherapy no ka mālama adjuvant ma hope o ka wehe ʻana a ʻaʻohe holomua ma hope o ka platinum-based adjuvant chemotherapy no nā poʻe maʻi makua me ka pae II a i IIIA* non-liʻiliʻi liʻiliʻi maʻi maʻi maʻi maʻi maʻi pūpū (NSCLC) nona nā maʻi koko he PD-L1 hōʻike ma ≥ 50% o ka nā pūnaʻi tumora (TCs).

ʻO TECENTRIQ kahi ʻano o ka mālama ʻana i ka maʻi immunotherapy. Hiki i ka Immunotherapy ke hana ma ke kōkua ʻana i ka ʻōnaehana pale e hakakā i nā maʻi maʻi maʻi. Hana ʻo TECENTRIQ ma ka hoʻopili ʻana i kahi protein i loko o kou kino i kapa ʻia ʻo Programmed Death Ligand-1, a i ʻole "PD-L1". ʻAʻole hana maikaʻi kēia protein i ka ʻōnaehana pale i loko o kou kino. Ma ka hoʻopili ʻana i ka protein, kōkua ʻo TECENTRIQ i kāu ʻōnaehana pale e hakakā i kou maʻi maʻi a hiki ke hoʻāla hou i ka pane ʻana i ka pale pale.

"He mea koʻikoʻi ke kaumaha o ka maʻi kanesa a ʻo ka hoʻomaʻamaʻa ʻana i kēlā me kēia pae he mea nui e hāʻawi i nā koho hou aʻe," wahi a Shem Singh, Luna Hoʻokele Lung Cancer Canada. "Me kēia ʻae ʻia, loaʻa i ka poʻe Kanada e noho ana me NSCLC kahi koho ʻē aʻe i ka wā e pili ana i ka mālama ʻana i ka maʻi i ka wā mua a hiki ke hoʻomaikaʻi i ka maikaʻi o ke ola."

Hoʻokumu ʻia ka ʻae ʻia ma ka ʻikepili mai ka Phase III IMpower010 study e hoʻohālikelike ana i ka TECENTRIQ i ka mālama kākoʻo maikaʻi loa (BSC) ma hope o ka adjuvant cisplatin-based chemotherapy i nā maʻi me ka maʻi maʻi maʻi ʻaʻole liʻiliʻi liʻiliʻi. I loko o kēia haʻawina, ua hōʻike ʻia kahi hoʻomaikaʻi maikaʻi ʻana i ka maʻi-free ola (DFS) ma ka lima TECENTRIQ i hoʻohālikelike ʻia me ka lima BSC i nā maʻi me PD-L1 TC ≥ 50% pae II a IIIA.

Loaʻa iā TECENTRIQ nā hōʻailona ʻeiwa i ʻae ʻia i kēia manawa ma Kanada, ʻelua o ia mau mea i ʻae ʻia me nā kūlana (NOC/c). No ka hoʻomaʻamaʻa ʻana o ka NSCLC mua, loaʻa ʻo TECENTRIQ i ʻekolu mau koho dosing, e hāʻawi ana i ka maʻalahi e koho i ka hoʻokele i kēlā me kēia ʻelua, ʻekolu a ʻehā paha pule.

"ʻO ka hoʻokomo ʻana i kahi lāʻau lapaʻau hou no nā maʻi maʻi maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi he nūhou maikaʻi," wahi a Peter Glazier, Hope Pelekikena Nui o ka Lung Health Foundation. "No ka hapa nui o nā mea maʻi me ka maʻi maʻi maʻi maʻi, ua liʻiliʻi ka holomua o ka mālama ʻana. Ma ke ʻano he hui i kālele ʻia i ka hoʻoponopono ʻana i nā āpau i ka pale ʻana, ka maʻi ʻana, a me ka mālama ʻana i ka maʻi maʻi maʻi ma Kanada, kākoʻo nui mākou i kahi koho lapaʻau hou no nā poʻe Kanada e noho nei me ka maʻi kanesa. “

Hiki ke hoʻokaʻawale nui ʻia ka maʻi ʻaʻai māmā i ʻelua mau ʻano nui: non-small cell (NSCLC) a me ka liʻiliʻi cell lung cancer (SCLC), me kahi o 88 pakeneka o nā hihia maʻi maʻi maʻi maʻi ma Kanada (koe ʻo Quebec) ʻo ia ka NSCLC. Hoʻokaʻawale ʻia ka maʻi kanesa ma nā pae, e like me ka pae I a hiki i ka IV, ma muli o ka nui o ka maʻi i loko o ke kino i ka manawa o ka maʻi.

"Ma ke ʻano he ʻoihana hoʻoponopono olakino, hauʻoli mākou e hāʻawi i kahi koho lapaʻau hou no ka poʻe Kanada e noho ana me ka maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi," wahi a Loredana Regep, Hope Pelekikena, Medical and Regulatory Affairs, Hoffmann-La Roche Limited. "Ke hāʻawi nei kēia ʻae hou i nā kauka i kahi koho ʻē aʻe no ka mālama ʻana i ka maʻi maʻi maʻi maʻi maʻi ma hope o nā makahiki he ʻumi me ka liʻiliʻi o ka mālama ʻana i kēia kūlana."

He aha e lawe ʻia mai kēia ʻatikala:

As an organization focused on addressing the gaps in the prevention, diagnosis, and care of lung disease in Canada, we are very supportive of a new treatment option for Canadians living with lung cancer.
In this study, a clinically meaningful improvement in disease-free survival (DFS) in the TECENTRIQ arm was shown compared to the BSC arm in patients with PD-L1 TC ≥ 50% stage II to IIIA.
Lung cancer is also classified in stages, as stage I through IV, based on the extent of disease in the body at the time of diagnosis.